文献速递肝病

m6A介导的糖异生酶PCK1上调可保护肝脏缺血再灌注损伤

m 6 A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury.
PubMed 文献 · Hepatology · 2023-12-12

研究分析人肝标本及小鼠模型发现,肝脏缺血再灌注损伤时糖异生限速酶PCK1显著诱导,高PCK1水平与更好的肝移植结局相关;甲基转移酶3介导的N6-甲基腺苷修饰促进PCK1上调,该轴激活对保护肝脏缺血再灌注损伤是必需的。

要点

  • 肝缺血再灌注损伤时糖异生限速酶PCK1显著诱导上调。
  • 人肝移植后标本高PCK1水平与更好的移植结局密切相关。
  • 甲基转移酶3/N6-甲基腺苷-PCK1-糖异生轴激活对保护肝缺血再灌注损伤是必需的。

核心结论

  • 激活甲基转移酶3/N6-甲基腺苷-PCK1-糖异生轴对保护肝脏缺血再灌注损伤是必需的,为减轻肝手术中肝脏缺血再灌注损伤提供了潜在干预途径。

研究设计与样本

  • 分析人肝缺血再灌注损伤前后标本,并结合小鼠肝缺血再灌注手术模型及缺氧/复氧处理的肝细胞进行验证。

主要发现

  • 人肝缺血再灌注损伤后糖异生限速酶PCK1显著诱导,小鼠肝缺血再灌注模型及缺氧/复氧肝细胞证实PCK1上调。
  • 人肝缺血再灌注后标本中高PCK1水平与更好的肝移植结局密切相关。
  • PCK1抑制剂阻断糖异生通过降低葡萄糖水平并加深乳酸积累加重肝缺血再灌注损伤,过表达PCK1则作用相反。
  • 甲基转移酶3介导的RNA N6-甲基腺苷修饰促进肝缺血再灌注损伤时PCK1上调,肝特异性敲除甲基转移酶3通过减少PCK1转录本N6-甲基腺苷沉积、降低PCK1 mRNA出核及表达水平恶化肝缺血再灌注损伤。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Ischemia-reperfusion (I/R) injury frequently occurs during liver surgery, representing a major reason for liver failure and graft dysfunction after operation. The metabolic shift from oxidative phosphorylation to glycolysis during ischemia increased glucose consumption and accelerated lactate production. We speculate that donor livers will initiate gluconeogenesis, the reverse process of glycolysis in theory, to convert noncarbohydrate carbon substrates (including lactate) to glucose to reduce the loss of hepatocellular energy and foster glycogen storage for use in the early postoperative period, thus improving post-transplant graft function. APPROACH AND RESULTS: By analyzing human liver specimens before and after hepatic I/R injury, we found that the rate-limiting enzyme of gluconeogenesis, PCK1, was significantly induced during liver I/R injury. Mouse models with liver I/R operation and hepatocytes treated with hypoxia/reoxygenation confirmed upregulation of PCK1 during I/R stimulation. Notably, high PCK1 level in human post-I/R liver specimens was closely correlated with better outcomes of liver transplantation. However, blocking gluconeogenesis with PCK1 inhibitor aggravated hepatic I/R injury by decreasing glucose level and deepening lactate accumulation, while overexpressing PCK1 did the opposite. Further mechanistic study showed that methyltransferase 3-mediated RNA N6-methyladinosine modification contributes to PCK1 upregulation during hepatic I/R injury, and hepatic-specific knockout of methyltransferase 3 deteriorates liver I/R injury through reducing the N6-methyladinosine deposition on PCK1 transcript and decreasing PCK1 mRNA export and expression level. CONCLUSIONS: Our study found that activation of the methyltransferase 3/N6-methyladinosine-PCK1-gluconeogenesis axis is required to protect against hepatic I/R injury, providing potential intervention approaches for alleviating hepatic I/R injury during liver surgery.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yu S, Liu X, Xu Y, et al. m 6 A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury. Hepatology. 2023. PMID: 38085830. doi:10.1097/HEP.0000000000000716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。